Evidence map›Paper›PMID 40235772›Full record

ArticleQuantitative imaging in medicine and surgery2025

Tumor habitat-derived radiomics features in pretreatment CT scans for predicting concurrent chemoradiotherapy responses in nasopharyngeal carcinoma: a retrospective study.

Xiaoyan Yin, Hui Sha, Xiujuan Cao, Xuanchu Ge, Tengxiang Li, Yongbin Cui, Shuli Li, Ruozheng Wang, Xue Sha

Abstract read
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoyan YinDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Hui ShaDepartment of Imaging Equipment, Hunan Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, China.
Xiujuan CaoDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xuanchu GeDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Tengxiang LiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yongbin CuiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Shuli LiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Ruozheng WangDepartment of Radiation Oncology, Affiliated Cancer Hospital of Xinjiang Medical University, Wulumuqi, China.
Xue ShaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a highly heterogeneous malignancy, characterized by significant variability in its biological and clinical features, which contribute to diverse treatment responses among patients. This study aimed to investigate intratumoral heterogeneity (ITH) in pretreatment computed tomography (CT) scans and test its performance for predicting responses to simultaneous chemoradiotherapy treatment in NPC patients. Methods: Pretreatment CT scans of 113 NPC patients were retrospectively analyzed at our center from March 2012 to September 2022. Radiomics features were selected from tumor and habitat regions to establish models. Both univariate and multivariate analyses were conducted to identify clinical risk indices related to treatment responses. Significant variables, including clinical variables, radiomics features, and habitat radiomics (H-Rad) features, were integrated into a joint predictive model, with its performance assessed using the area under the receiver operating characteristic (ROC) curve (AUC). Results: A total of ten prediction models were constructed, including six radiomics models [support vector machine (SVM), random forest, extra trees, extreme gradient boost (XGBoost), light gradient boosting machine (LightGBM), and habitat model] and one joint predictive model. The ExtraTrees model performed exceptionally well, resulting in AUCs of 0.969 and 0.894 in the training and testing cohorts, respectively. This indicates its strong ability to effectively predict between treatment responses. In the training cohort, the joint model demonstrated superior predictive accuracy with the highest AUC of 0.961. Additionally, the HabitatMean model showed excellent performance, with an AUC of 0.944. Overall, the joint model demonstrated robustness and superior integration of various features for predictive analysis, with the highest AUCs of 0.961 and 0.861 in the training and testing cohorts, respectively. Conclusions: A model that integrates conventional radiomics (C-Rad), a quantitative CT-based measure of ITH, and clinical variables has shown significant accuracy in predicting treatment response to chemoradiotherapy in NPC patients.

Indexed as

chemoradiotherapy responsehabitat radiomics features (H-Rad features)intratumoral heterogeneity (ITH)Nasopharyngeal carcinoma (NPC)

Identifiers

PMID40235772
PMCPMC11994483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.